Pfizer released more information from its clinical trial of a COVID pill which — if given within three days after the onset of symptoms — reduces the risk of hospitalization and death by 89 percent.
Called Paxlovid, it works by preventing the virus from making copies of itself.
Now the company waits for FEDA approval, which could come as early as this week.
Experts say an antiviral pill for Covid would have a major impact on the pandemic by making treatment available at home. Current treatments are available only by injection or IV.